Detailed information about the 100 most recent patent applications.
| Application Number | Title | Filing Date | Disposal Date | Disposition | Time (months) | Office Actions | Restrictions | Interview | Appeal |
|---|---|---|---|---|---|---|---|---|---|
| 18630105 | PHARMACEUTICAL FORMULATIONS CONTAINING GABOXADOL FOR THERAPEUTIC TREATMENT | April 2024 | September 2025 | Abandon | 18 | 0 | 1 | No | No |
| 18627508 | Implantable Device for Sustained Release of a Macromolecular Drug Compound | April 2024 | September 2025 | Allow | 17 | 2 | 0 | No | No |
| 18586970 | SUCKABLE AND/OR MELT-IN-MOUTH TABLET BASED ON HYALURONIC ACID AND CHONDROITIN SULPHATE AND SALTS THEREOF | February 2024 | October 2025 | Allow | 20 | 3 | 0 | No | No |
| 18437420 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | February 2024 | September 2024 | Allow | 8 | 0 | 0 | No | No |
| 18402862 | Methods And Kits For Reducing Microplastics Levels And/Or Reducing Or Minimizing Microplastics Accumulation Rates In Subjects | January 2024 | December 2025 | Allow | 23 | 0 | 0 | No | No |
| 18386399 | ETHYL 2-[9-(2-HYDROXYQUINOLIN-3-YL)-1,8-DIOXO-3,4,9,10-TETRAHYDROACRIDINE-10-YL]-ACETATE AS AN ANTIMICROBIAL COMPOUND | November 2023 | March 2024 | Allow | 4 | 1 | 0 | No | No |
| 18496821 | 4,5-BIS(4-METHOXYPHENYL)-1-HEXYL-2-(4-NITROPHENYL)-1H-IMIDAZOLE AS AN ANTIMICROBIAL COMPOUND | October 2023 | February 2024 | Allow | 4 | 1 | 0 | No | No |
| 18493075 | LIPSTICK | October 2023 | February 2026 | Allow | 28 | 0 | 0 | No | No |
| 18493072 | 2-(BENZO[D]OXAZOL-2-YL)-N'-(PICOLINOYLOXY)ACETIMIDAMIDE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18381454 | 9-(2-HYDROXYPHENYL)-10-[3-(DIMETHYLAMINO)PROPYL]-3,4,6,7,9,10- HEXAHYDROACRIDINE-1,8(2H,5H)-DIONE AS AN ANTIMICROBIAL COMPOUND | October 2023 | January 2024 | Allow | 3 | 0 | 0 | No | No |
| 18373611 | METHODS OF INCREASING MAGNESIUM BIOAVAILABILITY AND ABSORPTION | September 2023 | September 2025 | Allow | 23 | 2 | 0 | No | No |
| 18466404 | COSMETIC PRODUCTS INCLUDING BIS-CARBOXY SILICONE POLYMER COMPONENT | September 2023 | April 2025 | Abandon | 19 | 2 | 0 | No | No |
| 18460941 | Ready-To-Use Potassium Phosphates In Sodium Chloride Solutions | September 2023 | December 2023 | Allow | 3 | 0 | 0 | No | No |
| 18360514 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | July 2023 | September 2024 | Allow | 14 | 1 | 0 | No | No |
| 18262131 | DRUG DELIVERY COMPOSITION, METHOD FOR PRODUCING SAME AND USE THEREOF | July 2023 | October 2025 | Allow | 27 | 0 | 0 | No | No |
| 18345919 | COMPOSITIONS AND METHODS COMPRISING ENERGY ABSORBING MATERIALS FOR FOLLICULAR DELIVERY | June 2023 | June 2025 | Allow | 24 | 2 | 1 | Yes | No |
| 18329268 | DRUG DELIVERY SYSTEM COMPRISING A NON-STEROIDAL ANTI-INFLAMMATORY (NSAID) AND A PROGESTOGENIC COMPOUND AND METHODS FOR MANUFACTURING | June 2023 | November 2024 | Abandon | 18 | 1 | 0 | No | No |
| 18322065 | DERMAL SKIN PROTECTANT AND CARRIER | May 2023 | May 2025 | Allow | 24 | 2 | 0 | Yes | No |
| 18315605 | Implantable Device for Sustained Release of a Macromolecular Drug Compound | May 2023 | January 2024 | Allow | 8 | 0 | 0 | No | No |
| 18312624 | WAX OF NATURAL ORIGIN FOR COSMETIC PRODUCTS | May 2023 | December 2025 | Allow | 31 | 0 | 1 | No | No |
| 18033144 | OIL-BASED COSMETIC | April 2023 | February 2026 | Abandon | 34 | 1 | 0 | No | No |
| 18136916 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | April 2023 | October 2023 | Allow | 5 | 1 | 0 | No | No |
| 18303138 | Process for Transfer Resistance Polymers in Pigmented Products | April 2023 | December 2025 | Abandon | 32 | 1 | 0 | No | No |
| 18191874 | AQUEOUS COSMETIC | March 2023 | April 2024 | Allow | 13 | 1 | 1 | No | No |
| 18121679 | NUTRACEUTICAL COMPOSITIONS AND METHODS FOR DIETARY ALLEVIATION OF POLYCYSTIC OVARY SYNDROME | March 2023 | October 2023 | Allow | 7 | 2 | 1 | Yes | No |
| 18245039 | SOLID FORMS OF A CDK4 INHIBITOR | March 2023 | November 2025 | Allow | 32 | 1 | 0 | No | No |
| 18179777 | COMPOSITIONS COMPRISING SILK FIBROIN PARTICLES AND USES THEREOF | March 2023 | August 2024 | Allow | 17 | 2 | 0 | No | No |
| 18168958 | PHARMACEUTICAL COMPOSITION COMPRISING EICOSAPENTAENOIC ACID AND NICOTINIC ACID AND METHODS OF USING SAME | February 2023 | October 2024 | Abandon | 20 | 1 | 1 | No | No |
| 18104950 | ANTIMICROBIAL COMPOSITION INCLUDING AN ACYL LACTYLATE AND A GLYCOL AND METHODS OF INHIBITING MICROBIAL GROWTH UTILIZING THE SAME | February 2023 | September 2025 | Allow | 32 | 4 | 0 | No | No |
| 18097097 | METHOD FOR PRODUCING POWDER LEADS AND PRODUCTS PRODUCED THEREWITH | January 2023 | May 2024 | Allow | 16 | 1 | 1 | No | No |
| 18005095 | FILM COATED TABLET | January 2023 | March 2026 | Allow | 38 | 2 | 0 | No | No |
| 18148860 | INJECTABLE PREPARATION | December 2022 | February 2024 | Allow | 14 | 1 | 0 | No | No |
| 18013764 | Use of Self-Assembled Nanocrystals | December 2022 | December 2025 | Abandon | 35 | 0 | 1 | No | No |
| 18012975 | Method for Treating Melanoma | December 2022 | January 2026 | Abandon | 36 | 1 | 0 | No | No |
| 18011215 | DRUG COMPRISING PLGA NANOPARTICLES LOADED WITH CAPE TARGETED WITH ANGIOPEP-2 PEPTIDE | December 2022 | December 2025 | Abandon | 36 | 1 | 0 | No | No |
| 18059008 | COMPOSITION FOR COATING TABLET | November 2022 | November 2025 | Abandon | 35 | 4 | 1 | No | No |
| 18070186 | ANTIMICROBIAL COMPLEXES | November 2022 | January 2024 | Abandon | 14 | 0 | 1 | No | No |
| 17999193 | PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING PANCREATIC CANCER ASSOCIATED WITH RON MUTATION AND METHOD USING SAME | November 2022 | December 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17981080 | SENSITIZING COMPOSITION USING ELECTROMAGNETIC WAVES FOR THERMAL THERAPY OF CANCERS, AND CANCER THERAPY USING SAME | November 2022 | May 2023 | Allow | 7 | 0 | 0 | No | No |
| 17915865 | PHYTOECDYSONES AND DERIVATIVES THEREOF FOR USE IN TREATING DISORDERED RESPIRATORY FUNCTION ON VIRAL INFECTION | September 2022 | October 2025 | Allow | 37 | 1 | 0 | No | No |
| 17950638 | NOVEL CERIUM OXIDE NANOCOMPLEX AND A COMPOSITION FOR PREVENTING OR TREATING CEREBRAL INFARCTION COMPRISING THE SAME | September 2022 | April 2024 | Abandon | 19 | 1 | 0 | No | No |
| 17911781 | IDEBENONE FOR THE TREATMENT OF ACUTE RESPIRATORY DISTRESS SYNDROME (ARDS) IN PATIENTS DIAGNOSED WITH A CORONAVIRUS INFECTION | September 2022 | September 2025 | Allow | 36 | 1 | 0 | No | No |
| 17945054 | Vitamins and Alpha Keto Acid Compositions for Use in a Treatment Program for Chronic Kidney Disease Patients | September 2022 | August 2024 | Allow | 23 | 2 | 0 | Yes | No |
| 17945043 | Vitamins and Alpha Keto Acid Compositions for Use in a Treatment Program for Chronic Kidney Disease Patients | September 2022 | May 2024 | Allow | 20 | 1 | 0 | Yes | No |
| 17908132 | COSMETIC COMPOSITION WITH OPTIMIZED STARCH AND COSMETIC APPLICATIONS THEREOF | August 2022 | October 2025 | Allow | 38 | 1 | 0 | Yes | No |
| 17893991 | DRY POWDER COMPOSITIONS OF TREPROSTINIL PRODRUGS AND METHODS OF USE THEREOF | August 2022 | May 2023 | Allow | 9 | 0 | 0 | No | No |
| 17798217 | OIL-IN-OIL EMULSIFIED COSMETIC | August 2022 | November 2025 | Abandon | 39 | 2 | 0 | No | No |
| 17881991 | DOUBLE-STRUCTURED STICK COSMETIC AND MANUFACTURING METHOD THEREOF | August 2022 | January 2024 | Allow | 18 | 1 | 1 | No | No |
| 17797637 | PHARMACEUTICAL COMPOSITION CONTAINING REGORAFENIB AND A STABILIZING AGENT | August 2022 | December 2025 | Abandon | 40 | 0 | 1 | No | No |
| 17876348 | DOSAGE FORM COATING COMPOSITION AND METHOD OF MAKING AND USING THE SAME | July 2022 | May 2025 | Abandon | 34 | 3 | 0 | No | Yes |
| 17790857 | SOLID LIP COSMETIC | July 2022 | July 2025 | Abandon | 37 | 2 | 0 | No | No |
| 17787998 | COLONIC PURGATIVE COMPOSITION | June 2022 | September 2025 | Abandon | 39 | 2 | 0 | Yes | No |
| 17842691 | Implantable Pharmaceutical Composition Prepared From Components Consisting of Calcium Sulfate Alpha-Hemihydrate, Vancomycin and Tobramycin | June 2022 | March 2024 | Abandon | 21 | 0 | 1 | No | No |
| 17783678 | DISPERSION SOLUTION OF COMPLEX OF CERIUM OXIDE NANOPARTICLE WITH PROTEIN, METHOD OF SCAVENGING REACTIVE SPECIES, AND METHOD OF PRODUCING DISPERSION SOLUTION OF COMPLEX OF CERIUM OXIDE NANOPARTICLE WITH PROTEIN | June 2022 | February 2026 | Allow | 44 | 1 | 1 | No | No |
| 17783945 | CELLULOSE NANOCRYSTAL EFFECT PIGMENTS FOR COSMETIC APPLICATIONS | June 2022 | October 2025 | Allow | 40 | 1 | 1 | No | No |
| 17757060 | DOSAGE FORM COMPRISING AN ALKALINE AGENT AND AN ENTERIC COATING LAYER | June 2022 | February 2026 | Allow | 45 | 2 | 1 | Yes | No |
| 17831955 | USE OF HIGHER DOSES OF MODIFIED RELEASE HUPERZINE FORMULATIONS | June 2022 | August 2025 | Allow | 39 | 5 | 0 | No | No |
| 17779566 | CO-AMORPHOUS FORMS OF BETA-LACTOGLOBULIN AND A DRUG SUBSTANCE | May 2022 | January 2026 | Allow | 44 | 2 | 1 | No | No |
| 17777925 | AQUEOUS MIXTURES COMPRISING CELLULOSE NANOCRYSTALS AND SULFONATED POLYESTER | May 2022 | September 2025 | Allow | 40 | 1 | 1 | Yes | No |
| 17772699 | DIETARY SUPPLEMENT | April 2022 | October 2025 | Allow | 42 | 4 | 0 | Yes | No |
| 17726312 | Clear Nail Top Coat Compositions And Methods Of Making | April 2022 | May 2025 | Abandon | 36 | 1 | 0 | No | No |
| 17769678 | Clear Nail Top Coat Compositions And Methods Of Making | April 2022 | June 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17716200 | CONTROLLED RELEASE SOLID DOSE FORMS | April 2022 | November 2025 | Abandon | 43 | 1 | 1 | No | No |
| 17711122 | STORAGE STABLE SINCALIDE FORMULATIONS | April 2022 | January 2023 | Allow | 9 | 1 | 0 | No | No |
| 17765196 | PROTOPANAXATRIOL (PPT)-TYPE COMPOUNDS AS ACTIVE INGREDIENTS IN INSECTICIDE PRODUCTS | March 2022 | March 2025 | Abandon | 36 | 0 | 1 | No | No |
| 17701004 | PHARMACEUTICAL COMPOSITIONS COMPRISING AFATINIB | March 2022 | September 2023 | Allow | 18 | 1 | 0 | No | No |
| 17761725 | ANTIPERSPIRANT COMPOSITIONS | March 2022 | December 2025 | Abandon | 45 | 3 | 0 | No | No |
| 17642589 | PROCESS FOR PRODUCING A PHARMACEUTICAL FORMULATION COMPRISING CRYSTALLINE AND AMORPHOUS FRACTIONS OF AN ACTIVE SUBSTANCE | March 2022 | December 2024 | Abandon | 33 | 0 | 1 | No | No |
| 17683840 | METHOD FOR PRODUCING WEARABLE COATING | March 2022 | May 2023 | Allow | 14 | 0 | 0 | No | No |
| 17652559 | SELF-THERAPEUTIC NANOPARTICLE FOR ENHANCED TOPICAL DELIVERY TO SKIN KERATINOCYTES AND TREATING SKIN INFLAMMATION | February 2022 | May 2025 | Allow | 38 | 4 | 1 | No | No |
| 17638538 | SOLID COMPOSITION CONTAINING AMORPHOUS, POORLY WATER-SOLUBLE MATERIAL, AND METHOD FOR PRODUCING SAME | February 2022 | July 2025 | Allow | 40 | 1 | 1 | No | No |
| 17637841 | SOLID COSMETIC | February 2022 | June 2025 | Allow | 40 | 2 | 0 | No | No |
| 17636661 | NO SCENT NO BITE | February 2022 | April 2025 | Abandon | 38 | 0 | 1 | No | No |
| 17636732 | METHOD FOR PRODUCING A BIOACTIVE COMPONENT-CONTAINING NANO-COMPOSITE, AND A MONTMORILLONITE-BASED, BIOACTIVE COMPONENT-CONTAINING NANO-COMPOSITE | February 2022 | May 2025 | Allow | 39 | 1 | 1 | No | No |
| 17633699 | DIETARY SUPPLEMENTS TO AMELIORATE DIETARY INADEQUACIES RELATED TO BRAIN HEALTH OR NEURODEGENERATIVE DISEASES, AND METHODS TO DESIGN DIETARY SUPPLEMENTS | February 2022 | January 2026 | Allow | 47 | 2 | 1 | Yes | No |
| 17633226 | NOVEL COMPOUNDS FOR SKIN LIGHTENING | February 2022 | March 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17629760 | MEDICATION COATED WITH HEMP OR OTHER CANNABINOID | January 2022 | April 2025 | Abandon | 38 | 1 | 1 | No | No |
| 17627493 | CHEWING GUM COMPOSITIONS FOR THE TREATMENT OF MENSTRUAL PAIN | January 2022 | April 2025 | Abandon | 39 | 1 | 0 | No | No |
| 17597526 | FOOD COMPOSITIONS FOR WEIGHT MANAGEMENT | January 2022 | February 2026 | Allow | 49 | 2 | 1 | No | No |
| 17646794 | OIL-DISPERSED COMPOSITION AND COSMETICS FOR LIP CARE USING THE SAME | January 2022 | November 2023 | Allow | 23 | 2 | 1 | No | No |
| 17566015 | METHODS OF TREATMENT USING ULTRASMALL NANOPARTICLES TO INDUCE CELL DEATH OF NUTRIENT-DEPRIVED CANCER CELLS VIA FERROPTOSIS | December 2021 | November 2023 | Allow | 22 | 1 | 0 | No | No |
| 17557105 | LONG WEAR LIQUID ANHYDROUS COMPOSITION | December 2021 | March 2024 | Allow | 26 | 1 | 1 | No | No |
| 17553648 | DEODORANT COMPOSITIONS | December 2021 | January 2025 | Abandon | 37 | 1 | 0 | No | No |
| 17550117 | EXTENDED RELEASE COMPOSITIONS COMPRISING PYRIDOSTIGMINE | December 2021 | January 2023 | Allow | 13 | 2 | 1 | Yes | No |
| 17549495 | ANTICANCER COMPOSITIONS | December 2021 | July 2024 | Abandon | 31 | 2 | 0 | No | No |
| 17618256 | DEODORANT COMPOSITIONS | December 2021 | January 2025 | Abandon | 38 | 1 | 0 | No | No |
| 17526266 | SUGAR-FREE LIP SCRUB COMPOSITIONS AND USES THEREOF | November 2021 | October 2023 | Abandon | 23 | 2 | 0 | Yes | No |
| 17610727 | Powder Cosmetic | November 2021 | July 2025 | Allow | 44 | 2 | 0 | No | No |
| 17513276 | METHODS OF INCREASING MAGNESIUM BIOAVAILABILITY AND ABSORPTION | October 2021 | September 2023 | Allow | 22 | 1 | 1 | No | No |
| 17507369 | PHARMACEUTICAL FORMULATIONS CONTAINING GABOXADOL FOR THERAPEUTIC TREATMENT | October 2021 | May 2024 | Abandon | 31 | 1 | 1 | No | No |
| 17502181 | DRUG DELIVERY CARRIER INCLUDING PLGA AND BETA-CYCLODEXTRIN CONTAINING DRUG | October 2021 | January 2024 | Abandon | 27 | 1 | 1 | No | No |
| 17501237 | STABLE BENZIMIDAZOLE FORMULATION | October 2021 | March 2026 | Allow | 53 | 5 | 0 | Yes | No |
| 17499001 | Ready-To-Use Potassium Phosphates In Sodium Chloride Solutions | October 2021 | September 2023 | Allow | 23 | 0 | 0 | No | No |
| 17490797 | METHOD FOR TREATING MYOPIA AND APPLICATION IN PREPARATION OF MEDICAMENT | September 2021 | May 2024 | Abandon | 31 | 2 | 1 | Yes | No |
| 17484725 | DRUG DELIVERY SYSTEM FOR TREATMENT OF CANCER | September 2021 | June 2025 | Allow | 44 | 2 | 0 | No | No |
| 17480892 | HAIR CONDITIONING COMPOSITION | September 2021 | April 2024 | Abandon | 30 | 2 | 0 | No | No |
| 17439829 | COMPOSITIONS COMPRISING CURCUMIN AND COENZYME Q10 | September 2021 | August 2024 | Abandon | 35 | 1 | 1 | No | No |
| 17476801 | TREATING MALE INFERTILITY SECONDARY TO SPERM OXIDATIVE STRESS | September 2021 | August 2025 | Abandon | 47 | 4 | 0 | Yes | No |
| 17475741 | LAVAGE TECHNIQUES AND VIRUCIDAL COMPOSITIONS COMPRISING HYPOCHLOROUS SOLUTIONS | September 2021 | March 2025 | Abandon | 42 | 3 | 0 | No | No |
| 17473826 | Dental Local Anesthetic Solution | September 2021 | February 2023 | Abandon | 17 | 2 | 1 | No | No |
This analysis examines appeal outcomes and the strategic value of filing appeals for examiner AL-AWADI, DANAH J.
With a 31.8% reversal rate, the PTAB reverses the examiner's rejections in a meaningful percentage of cases. This reversal rate is below the USPTO average, indicating that appeals face more challenges here than typical.
Filing a Notice of Appeal can sometimes lead to allowance even before the appeal is fully briefed or decided by the PTAB. This occurs when the examiner or their supervisor reconsiders the rejection during the mandatory appeal conference (MPEP § 1207.01) after the appeal is filed.
In this dataset, 21.2% of applications that filed an appeal were subsequently allowed. This appeal filing benefit rate is below the USPTO average, suggesting that filing an appeal has limited effectiveness in prompting favorable reconsideration.
⚠ Appeals to PTAB face challenges. Ensure your case has strong merit before committing to full Board review.
⚠ Filing a Notice of Appeal shows limited benefit. Consider other strategies like interviews or amendments before appealing.
Examiner AL-AWADI, DANAH J works in Art Unit 1615 and has examined 802 patent applications in our dataset. With an allowance rate of 52.6%, this examiner allows applications at a lower rate than most examiners at the USPTO. Applications typically reach final disposition in approximately 34 months.
Examiner AL-AWADI, DANAH J's allowance rate of 52.6% places them in the 14% percentile among all USPTO examiners. This examiner is less likely to allow applications than most examiners at the USPTO.
On average, applications examined by AL-AWADI, DANAH J receive 2.68 office actions before reaching final disposition. This places the examiner in the 78% percentile for office actions issued. This examiner issues more office actions than most examiners, which may indicate thorough examination or difficulty in reaching agreement with applicants.
The median time to disposition (half-life) for applications examined by AL-AWADI, DANAH J is 34 months. This places the examiner in the 42% percentile for prosecution speed. Prosecution timelines are slightly slower than average with this examiner.
Conducting an examiner interview provides a +15.2% benefit to allowance rate for applications examined by AL-AWADI, DANAH J. This interview benefit is in the 55% percentile among all examiners. Recommendation: Interviews provide an above-average benefit with this examiner and are worth considering.
When applicants file an RCE with this examiner, 18.4% of applications are subsequently allowed. This success rate is in the 17% percentile among all examiners. Strategic Insight: RCEs show lower effectiveness with this examiner compared to others. Consider whether a continuation application might be more strategic, especially if you need to add new matter or significantly broaden claims.
This examiner enters after-final amendments leading to allowance in 20.3% of cases where such amendments are filed. This entry rate is in the 25% percentile among all examiners. Strategic Recommendation: This examiner rarely enters after-final amendments compared to other examiners. You should generally plan to file an RCE or appeal rather than relying on after-final amendment entry. Per MPEP § 714.12, primary examiners have discretion in entering after-final amendments, and this examiner exercises that discretion conservatively.
When applicants request a pre-appeal conference (PAC) with this examiner, 84.2% result in withdrawal of the rejection or reopening of prosecution. This success rate is in the 65% percentile among all examiners. Strategic Recommendation: Pre-appeal conferences show above-average effectiveness with this examiner. If you have strong arguments, a PAC request may result in favorable reconsideration.
This examiner withdraws rejections or reopens prosecution in 62.1% of appeals filed. This is in the 40% percentile among all examiners. Of these withdrawals, 58.3% occur early in the appeal process (after Notice of Appeal but before Appeal Brief). Strategic Insight: This examiner shows below-average willingness to reconsider rejections during appeals. Be prepared to fully prosecute appeals if filed.
When applicants file petitions regarding this examiner's actions, 61.6% are granted (fully or in part). This grant rate is in the 66% percentile among all examiners. Strategic Note: Petitions show above-average success regarding this examiner's actions. Petitionable matters include restriction requirements (MPEP § 1002.02(c)(2)) and various procedural issues.
Examiner's Amendments: This examiner makes examiner's amendments in 3.0% of allowed cases (in the 79% percentile). Per MPEP § 1302.04, examiner's amendments are used to place applications in condition for allowance when only minor changes are needed. This examiner frequently uses this tool compared to other examiners, indicating a cooperative approach to getting applications allowed. Strategic Insight: If you are close to allowance but minor claim amendments are needed, this examiner may be willing to make an examiner's amendment rather than requiring another round of prosecution.
Quayle Actions: This examiner issues Ex Parte Quayle actions in 0.5% of allowed cases (in the 55% percentile). This examiner issues Quayle actions more often than average when claims are allowable but formal matters remain (MPEP § 714.14).
Based on the statistical analysis of this examiner's prosecution patterns, here are tailored strategic recommendations:
Not Legal Advice: The information provided in this report is for informational purposes only and does not constitute legal advice. You should consult with a qualified patent attorney or agent for advice specific to your situation.
No Guarantees: We do not provide any guarantees as to the accuracy, completeness, or timeliness of the statistics presented above. Patent prosecution statistics are derived from publicly available USPTO data and are subject to data quality limitations, processing errors, and changes in USPTO practices over time.
Limitation of Liability: Under no circumstances will IronCrow AI be liable for any outcome, decision, or action resulting from your reliance on the statistics, analysis, or recommendations presented in this report. Past prosecution patterns do not guarantee future results.
Use at Your Own Risk: While we strive to provide accurate and useful prosecution statistics, you should independently verify any information that is material to your prosecution strategy and use your professional judgment in all patent prosecution matters.